Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Usana Health Sciences (USNA) over the last 15 years, with Q3 2025 value amounting to -$979000.0.

  • Usana Health Sciences' Cash from Financing Activities fell 115512.82% to -$979000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.1 million, marking a year-over-year decrease of 14472.05%. This contributed to the annual value of $9.6 million for FY2024, which is 16709.98% up from last year.
  • Latest data reveals that Usana Health Sciences reported Cash from Financing Activities of -$979000.0 as of Q3 2025, which was down 115512.82% from -$38.6 million recorded in Q2 2025.
  • Usana Health Sciences' 5-year Cash from Financing Activities high stood at $22.9 million for Q4 2024, and its period low was -$122.4 million during Q1 2022.
  • Moreover, its 5-year median value for Cash from Financing Activities was -$3.2 million (2023), whereas its average is -$16.6 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 2635681.82% in 2023, then soared by 338480.24% in 2024.
  • Usana Health Sciences' Cash from Financing Activities (Quarter) stood at -$70.5 million in 2021, then soared by 99.79% to -$150000.0 in 2022, then soared by 538.67% to $658000.0 in 2023, then surged by 3384.8% to $22.9 million in 2024, then tumbled by 104.27% to -$979000.0 in 2025.
  • Its Cash from Financing Activities stands at -$979000.0 for Q3 2025, versus -$38.6 million for Q2 2025 and -$14.5 million for Q1 2025.